Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

Merck announced it will acquire UK-based Verona Pharma for approximately $10 billion, representing a 23% premium at $107 per American depository share. This strategic move aims to significantly bolster Merck's respiratory treatment portfolio and diversify its revenue base ahead of Keytruda's patent expiry beginning in 2028. Verona's key asset, Ohtuvayre, an approved non-steroid COPD treatment, generated $42.3 million in sales last year and is projected to achieve peak annual sales exceeding $3 billion, making it a crucial addition to Merck's long-term growth strategy.

Analysis

Merck is executing a significant strategic acquisition by purchasing Verona Pharma for approximately $10 billion, a move designed to diversify its revenue stream ahead of the 2028 patent expiration of its leading cancer drug, Keytruda, which generated nearly $30 billion in 2024 sales. The deal, priced at a 23% premium of $107 per American depository share, represents Merck's largest M&A activity since its $10.8 billion acquisition of Prometheus Biosciences in 2023, underscoring an aggressive strategy to fill its impending revenue gap. The core asset acquired is Verona's Ohtuvayre, a recently approved, non-steroid treatment for Chronic Obstructive Pulmonary Disease (COPD). While Ohtuvayre's initial annual sales were a modest $42.3 million, its value lies in its growth potential, with Jefferies analysts projecting peak annual sales could exceed $3 billion. This acquisition not only adds a high-potential asset but also strategically strengthens Merck's existing respiratory portfolio, which includes Winrevair and Enflonsia, solidifying its position in the chronic lung disease market.

Key Decisions for Investors

• Investors in Merck should view this as a constructive, long-term strategic move to address the well-known Keytruda patent cliff, with execution on Ohtuvayre's commercialization now becoming a key performance indicator to monitor.
• For Verona Pharma shareholders, the acquisition at a 23% premium offers a clear and attractive exit, and the primary consideration is capturing this value by holding through the deal's completion.
• The deal reinforces the ongoing M&A trend in the biopharmaceutical sector, suggesting that mid-sized companies with approved, high-potential assets in specialty therapeutic areas remain prime acquisition targets for large-cap firms facing patent expiries.